Walleye Capital
IOVA icon

Walleye Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Walleye Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351 Sell
100
-162,800
-100% -$521K ﹤0.01% 4275
2025
Q4 		$445K Buy
162,900
+159,200
+4,303% +$368K ﹤0.01% 3030
2025
Q3 		$8.03K Buy
+3,700
New +$8.74K ﹤0.01% 4290
2025
Q1 		– Sell
-34,200
Closed -$253K – 4651
2024
Q4 		$253K Buy
+34,200
New +$317K ﹤0.01% 3571
2024
Q3 		– Sell
-28,600
Closed -$229K – 5562
2024
Q2 		$229K Sell
28,600
-42,200
-60% -$452K ﹤0.01% 4196
2024
Q1 		$1.05M Buy
70,800
+67,400
+1,982% +$784K ﹤0.01% 2541
2023
Q4 		$27.6K Sell
3,400
-1,600
-32% -$8.37K ﹤0.01% 4413
2023
Q3 		$22.8K Sell
5,000
-18,700
-79% -$122K ﹤0.01% 4363
2023
Q2 		$167K Buy
+23,700
New +$170K ﹤0.01% 3189

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Walleye Capital's IOVA Position: Q1 2026 in Review

Walleye Capital reduced its Iovance Biotherapeutics (IOVA) stake by 96% in Q1 2026, selling an estimated $2.53M and leaving 30,356 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #3644.

Walleye Capital first reported a position in IOVA in Q1 2021 and has held it in 12 quarters since. The position peaked at $4.51M in Q4 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Walleye Capital held 30,356 shares of Iovance Biotherapeutics worth $107K as of Q1 2026.
  • Walleye Capital sold 792,398 Iovance Biotherapeutics shares in Q1 2026, an estimated $2.53M.
  • Iovance Biotherapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3644 holding.
  • Walleye Capital first reported a position in Iovance Biotherapeutics in Q1 2021 and has held it in 12 quarters since.
  • Walleye Capital's Iovance Biotherapeutics position peaked at $4.51M in Q4 2021.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.